Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination.
Ebola
antibody
natural killer cell
vaccine
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
08 04 2021
08 04 2021
Historique:
received:
05
09
2019
accepted:
09
12
2019
pubmed:
11
12
2019
medline:
11
2
2022
entrez:
11
12
2019
Statut:
ppublish
Résumé
Antibody Fc-mediated functions, such as antibody-dependent cellular cytotoxicity, contribute to vaccine-induced protection against viral infections. Fc-mediated function of anti-Ebola glycoprotein (GP) antibodies suggest that Fc-dependent activation of effector cells, including natural killer (NK) cells, could play a role in vaccination against Ebola virus disease. We analyzed the effect on primary human NK cell activation of anti-Ebola GP antibody in the serum of United Kingdom-based volunteers vaccinated with the novel 2-dose heterologous adenovirus type 26.ZEBOV, modified vaccinia Ankara-BN-Filo vaccine regimen. We demonstrate primary human NK cell CD107a and interferon γ expression, combined with down-regulation of CD16, in response to recombinant Ebola virus GP and post-vaccine dose 1 and dose 2 serum samples. These responses varied significantly with vaccine regimen, and NK cell activation was found to correlate with anti-GP antibody concentration. We also reveal an impact of NK cell differentiation phenotype on antibody-dependent NK cell activation, with highly differentiated CD56dimCD57+ NK cells being the most responsive. These findings highlight the dual importance of vaccine-induced antibody concentration and NK cell differentiation status in promoting Fc-mediated activation of NK cells after vaccination, raising a potential role for antibody-mediated NK cell activation in vaccine-induced immune responses.
Sections du résumé
BACKGROUND
Antibody Fc-mediated functions, such as antibody-dependent cellular cytotoxicity, contribute to vaccine-induced protection against viral infections. Fc-mediated function of anti-Ebola glycoprotein (GP) antibodies suggest that Fc-dependent activation of effector cells, including natural killer (NK) cells, could play a role in vaccination against Ebola virus disease.
METHODS
We analyzed the effect on primary human NK cell activation of anti-Ebola GP antibody in the serum of United Kingdom-based volunteers vaccinated with the novel 2-dose heterologous adenovirus type 26.ZEBOV, modified vaccinia Ankara-BN-Filo vaccine regimen.
RESULTS
We demonstrate primary human NK cell CD107a and interferon γ expression, combined with down-regulation of CD16, in response to recombinant Ebola virus GP and post-vaccine dose 1 and dose 2 serum samples. These responses varied significantly with vaccine regimen, and NK cell activation was found to correlate with anti-GP antibody concentration. We also reveal an impact of NK cell differentiation phenotype on antibody-dependent NK cell activation, with highly differentiated CD56dimCD57+ NK cells being the most responsive.
CONCLUSIONS
These findings highlight the dual importance of vaccine-induced antibody concentration and NK cell differentiation status in promoting Fc-mediated activation of NK cells after vaccination, raising a potential role for antibody-mediated NK cell activation in vaccine-induced immune responses.
Identifiants
pubmed: 31821493
pii: 5672569
doi: 10.1093/infdis/jiz657
pmc: PMC8030727
doi:
Substances chimiques
Antibodies, Viral
0
Ebola Vaccines
0
Glycoproteins
0
Viral Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1171-1182Subventions
Organisme : Medical Research Council
ID : G1000808
Pays : United Kingdom
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Nature. 2014 Oct 2;514(7520):47-53
pubmed: 25171469
J Immunol. 2018 Apr 15;200(8):2738-2747
pubmed: 29491009
Front Immunol. 2016 Sep 26;7:384
pubmed: 27725819
JAMA. 2016 Apr 19;315(15):1610-23
pubmed: 27092831
Sci Rep. 2017 Mar 30;7:45552
pubmed: 28358050
J Infect Dis. 2019 Jun 5;220(1):46-56
pubmed: 30796818
J Pathol. 2015 Jan;235(2):288-97
pubmed: 25205255
Sci Rep. 2016 Feb 15;6:21674
pubmed: 26876974
PLoS Pathog. 2014 Oct 16;10(10):e1004441
pubmed: 25329659
Blood. 2012 Jun 14;119(24):5640-9
pubmed: 22535666
J Infect Dis. 2007 Nov 15;196 Suppl 2:S430-7
pubmed: 17940980
Cell Host Microbe. 2018 Aug 8;24(2):221-233.e5
pubmed: 30092199
J Virol. 2019 Feb 19;93(5):
pubmed: 30541850
Cell. 2018 Aug 9;174(4):938-952.e13
pubmed: 30096313
J Immunol. 2015 May 15;194(10):4657-67
pubmed: 25855356
J Infect Dis. 2016 Sep 15;214(6):945-52
pubmed: 27354365
PLoS Pathog. 2013;9(5):e1003389
pubmed: 23737747
J Virol. 2019 Mar 5;93(6):
pubmed: 30567978
JAMA. 2017 Mar 14;317(10):1075-1077
pubmed: 28291882
J Immunol Methods. 2018 Sep;460:10-16
pubmed: 29894746
Trends Microbiol. 2019 Jan;27(1):8-16
pubmed: 30201511
Hum Immunol. 2016 Feb;77(2):165-71
pubmed: 26582002
J Immunol. 2016 Aug 15;197(4):1507-16
pubmed: 27385782
Eur J Immunol. 2018 Jan;48(1):50-65
pubmed: 28960320
Blood. 2013 May 2;121(18):3599-608
pubmed: 23487023
J Exp Med. 2019 Jun 3;216(6):1280-1290
pubmed: 30979790
Cell Rep. 2017 Aug 29;20(9):2251-2261
pubmed: 28854372
J Clin Invest. 2016 Feb;126(2):605-10
pubmed: 26731473
Oncotarget. 2016 Dec 27;7(52):86359-86373
pubmed: 27861156
J Infect Dis. 2019 Jun 5;220(1):57-67
pubmed: 30796816
Immunity. 2015 Mar 17;42(3):443-56
pubmed: 25786176
J Biol Chem. 2002 Jul 26;277(30):26733-40
pubmed: 11986321
PLoS Pathog. 2012;8(12):e1003065
pubmed: 23271969
Nat Immunol. 2018 Nov;19(11):1169-1178
pubmed: 30333617
Blood. 2006 Oct 15;108(8):2648-54
pubmed: 16825493
Science. 2016 Mar 18;351(6279):1339-42
pubmed: 26917593
Eur J Immunol. 2017 Jun;47(6):1040-1050
pubmed: 28383105
J Cell Biol. 2018 Sep 3;217(9):3267-3283
pubmed: 29967280